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Oral Presentations 25lower after allogeneic HSCT. Consequently, progression-free sur-
vival rates are similar in both transplant groups.
Autologous AllogeneicOutcome Probability (95% Confidence Interval)Burkitt N 5 33 N 5 45
TRM @ 100-days 9% (2–21) 11% (4–22)
Relapse @ 5-years 54% (35–73) 47% (31–63)
PFS @ 5-years 37% (21–55) 35% (22–50)
DLBCL N 5 48 N 5 18
TRM @ 100-days 8% (2–18) 11% (1–29)
Relapse @ 5-years 28% (16–42) 33% (14–56)
PFS @ 5-years 55% (40–69) 44% (23–67)
Lymphoblastic N 5 23 N 5 40
TRM @ 100-days 9% (1–23) 25% (13–39)
Relapse @ 5-years 58% (34–81) 15% (6–28)
PFS @ 5-years 33% (15–55) 50% (35–65)
ALCL N 5 27 N 5 15
TRM @ 100-days 4% (0–14) 21% (5–43)
Relapse @ 5-years 45% (25–65) 15% (2–38)
PFS @ 5-years 43% (24–63) 55% (28–80)61
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Pentostatin, an irreversible adenosine deaminase inhibitor, was
shown in a phase II study to be effective for steroid-refractory
cGVHD. Our goal was to determine efficacy and toxicity of pentos-
tatin for steroid-refractory cGVHD in children.
Eligible patients were\ 21 years, with refractory cGVHD, hav-
ing failed#2 prior regimens. Subjects were to get 4 mg/m2 pentos-
tatin IV every 2 weeks for at least 6months. If subjects had complete
response(CR) at 6 months, pentostatin was stopped; with partial re-
sponse(PR, improvement in $1 site without progression in other)
or stable disease, treatment continued for 12months.With progres-
sion, pentostatin was discontinued. Tapering of corticosteroids be-
gan 8–12 weeks after starting study; other immunosuppression was
tapered after 3 months. Change in GVHD status was assessed every
3 months for each involved organ(skin, oral, eyes, liver, joint, GI,
pulmonary). Grades were 0(not involved), 1(mild), 2(moderate),
and 3(severe), with subject’s last available evaluation used to deter-
mine response.
A total of 51 subjects were enrolled in 26 sites; 43 are reported(41
completed therapy/off-study; 2 on-study but . 6 months therapy).
8 are too early to evaluate. Median age was 9.5 years(0.9–20.7).
GVHDgrade wasmoderate in 17, severe in 26.Most were receiving
corticosteroids at time of study entry(40); other immunosuppres-
sion was: MMF(23), FK-506(23), CSA(11) and other(5).
Subjects received a median of 12 pentostatin doses(range 1–26)
over a median of 6 months(0.5–12). Overall response rate was
44%(28% PR, 16% CR). 2 subjects had stable disease and 9 went
off-study before the 3-month evaluation(7 progression, 2 toxicity).
The table shows response by system in the 34 subjects that com-
pleted the 3 month evaluation. Skin and oral had the most notable
response. By study completion, 8 subjects were off corticosteroids,
and 20 were on\ 0.5 mg/kg/day. Most common severe adverse
events were infection(11 documented[bacterial 5 8, fungal5 1, vi-
ral 5 2]). Ten subjects were removed due to toxicity and 2 due to
cancer relapse; 6 had had a response to pentostatin. Four deaths oc-
curred either on-study or within 28 days after last dose from infec-
tion(3), leukoencephalopathy(1).Pentostatin has activity in the treatment of refractory cGVHD in
children, with acceptable toxicity. Skin and oral cGVHD has the
most benefit. Adding pentostatin allows significant tapering of cor-
ticosteroids. Further follow-up is needed to evaluate durability of
response.Response by System in the 34 Subjects on Study at least through 3-month
Evaluation
Total StableSystem Manifestations N Response Progression DiseaseSkin Rash/Lichenoid 29 17 9 3Fasciitis/
Sclerosis21 15 3 3Oral symptoms/
lichenoid and/or
erythema19 15 2 2Ocular symptoms/need
for treatment16 7 5 4Joints Arthralgias/
Contractures16 6 6 4Gastrointestinal Vomiting/
Abdominal Pain/
Diarrhea15 7 6 2Liver Total Bilirubin 3 0 2 162
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Graft versusHostDisease (GVHD) is still one of themost impor-
tant risk factor for mortality and long term morbidity in children
and adolescents undergoing allogeneic stem cell transplantation
(SCT) from unrelated donors (UD). In 2003 the Berlin-Frank-
furt-Muenster (BFM)-Study Group initiated a prospective, interna-
tional, multicenter trial on allogeneic SCT in children with high-
risk ALL (ALL-SCT-BFM 2003). In this ongoing trial main goals
are the standardisation and harmonisation of the SCT procedure
and the question, if SCT from a HLA-genoidentical sibling donor
(MSD) is equivalent to SCT from a matched donor (MD). A MD
was defined as related or donor with 10/10 or 9/10 HLA matches,
determined by HLA high-resolution typing (4 digits/allel: A, B,
C, DRB1 and DQB1). Between September 2003 and June 2007,
381 patients (185 in CR1, 196 in CR2 or after subsequent relapse)
were recruited by 27 participating SCT centers in Austria, Germany
and Switzerland. Indications for SCT were poor response to induc-
tion treatment, cytogenetic aberrations, early bone marrow relapse,
or any subsequent ALL relapse. GVHD-prophylaxis for patients
undergoing MSD-SCT consisted of only CSA to augment the
GVL-effect. Patients transplanted from MD received CSA, short
MTX and rabbit ATG. The recommended conditioning regimens
were TBI1VP16 for patients . 2 years; in children younger than
2 years, TBI was substituted by busulfan and cyclophosphamide.
Unmanipulated bone marrow was used in 73% of MSD- and
MD-SCT as recommended by the protocol. No significant differ-
ence in the occurrence of acute and chronic GVHD was observed:
after MSD-SCT: 20% of patients did not develop any aGVHD,
37% had grade I, 31% grade II, 4% grade III and 4% grade IV. Af-
ter MD-SCT, 26% had no GVHD, 39% grade I, 27% grade II, 5%
grade III and 3% grade IV. Limited cGVHD was observed in 7%
vs. 8% and extensive cGVHD in 16% vs. 5% after MSD and MD
